Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
03 May 2023
REPROCELL USA, a CRO, has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)”. The...
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama
28 February 2023
On February 26, 2023, REPROCELL celebrated its 20th anniversary. I would like to express our sincere gratitude to our customers who use our products and services, our shareholders who have invested in us with high expectations for our futur...
End of Q3 update from REPROCELL (2022-23)
12 December 2022
The year might be coming to a close, but we’re not winding down at REPROCELL. The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This includes our memb...
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
09 December 2022
Silo Pharma, Inc. has announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. Conducted in partners...
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
23 November 2022
Yokohama Japan, 23 November 2022: REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings. Histocell is a CDMO based in Bilbao, Spain, with an authorized Advanced ...
Building economic resilience and unleashing productivity through digital innovation
09 November 2022
UK enterprises are facing a number of disruptive forces that necessitate transformation at pace – macro-economic challenges, socio-political challenges, and the focus on our own resilience. Industries from across the country are in the grip...
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
13 October 2022
Yokohama, Japan, 13 October 2022: REPROCELL Inc. and JTB Corp. will begin marketing "Personal iPS" (REPROCELL's iPSC storage and production service) overseas through the Japan Medical & Health Tourism Center (JMHC): a medical coordination d...
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
05 October 2022
Yokohama Japan, 5 October 2022: REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to make accessible REPROCELL’s unique induced Pluripotent Stem Cells (iPSCs) tec...
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
04 October 2022
YOKOHAMA, Japan: REPROCELL Inc. and San Antonio, Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. The agreement will expand REPROCELL’s global biomanufacturing ser...
End of Q2 update from REPROCELL (2022-23)
03 October 2022
We're halfway through the financial year and there are only three months left in 2022. Time is racing but REPROCELL has managed to pack in a lot since our last update, including three conferences and the launch of our clinical laboratory se...